Search results

Select how you would like to sort the search results
Journal
Clinical Chemistry Cover Image
Clinical Chemistry is a high-impact peer-reviewed publication, ranked as the most cited journal in the fields of clinical chemistry, clinical or anatomic pathology, analytical chemistry, transfusion medicine, and clinical microbiology.
Journal
The Journal of Applied Laboratory Medicine Cover Image
The Journal of Applied Laboratory Medicine is an online-only, peer-reviewed publication showcasing clinically relevant laboratory topics in applied and translational research.
Journal Article
Haikun Zhang and others
Clinical Chemistry, hvag133, https://doi.org/10.1093/clinchem/hvag133
Published: 16 November 2026
Image
Published: 16 November 2026
Fig. 2. Pathogen-specific microbial abundance (genus-level) across sepsis, noninfection, and NTC samples. Boxplots show the relative abundance of pathogen-associated genera detected in plasma cfDNA across 3 groups. Pathogens in sepsis samples correspond to those confirmed by microbiology culture at coincide
Image
Published: 16 November 2026
Fig. 4. Comparative analysis of 2-mer microbial end motif patterns in pathogen- and contaminant-derived mDNA. (A), CV of 2-mer end motifs in culture-proven pathogens from sepsis samples and contaminants (top 30 genera identified from pooled NTCs) across pooled NTC, noninfection, and sepsis groups. (B), The
Image
Published: 16 November 2026
Fig. 6. Microbial fragment end motifs improve detection of pathogen-specific mDNA in sepsis relative to noninfection samples. (A), Staphylococcus abundance at the genus level across sepsis samples, noninfection samples, and NTCs. Sepsis samples shown are from patients with microbiologically confirmed Sta
Image
Published: 16 November 2026
Fig. 3. Dinucleotide microbial end motif patterns at the 5′ and 3′ fragment ends. (A), Heatmap shows the O/E ratios of 2-mer end motifs for pathogenic genera (5 unique genera from culture-positive patients) and contaminating genera (top 30 abundant genera from pooled NTCs). Motif patterns are shown separate
Image
Published: 16 November 2026
Fig. 2. Bland–Altman plots illustrating agreement with limits of agreement between POCT devices and laboratory measurements for serum creatinine. NovaMax Pro: Data points are illustrated in yellow; blue dashed line indicates mean difference; green dashed line indicates 95% limits of agreement. Epoc Blood An
Image
Published: 16 November 2026
Fig. 3. Bland–Altman plots assessing agreement between POCT devices’ capillary and venous samples for CKD-EPI 2021 eGFR compared to laboratory results. NovaMax Pro: Data points are illustrated in yellow; blue dashed line indicates mean difference; green dashed line indicates 95% limits of agreement. Epoc B
Image
Published: 16 November 2026
Fig. 1. Flow diagram illustrating participants included with laboratory samples and number of participants who had paired capillary and venous point-of-care samples for NovaMax Pro and Epoc Blood Analysis System. Flow diagram illustrating participants included with laboratory samples and number of partic
Image
Published: 16 November 2026
Fig. 1. Overview of the study cohort, sample processing, and computational workflow. Plasma samples were obtained from 11 patients in the intensive care unit, and 6 NTCs were processed in parallel to assess potential contamination. Plasma samples were extracted, followed by ssDNA library preparation with si
Image
Published: 16 November 2026
Fig. 5. Mononucleotide microbial end motif patterns at the 5′ and 3′ fragment ends. (A), Heatmap shows the O/E ratios of 1-mer end motifs for contaminating genera and pathogenic genera. (B), Boxplots compare the O/E ratios of all four 1-mer end motifs between pathogens and contaminants at both the 5′ and 3′
Journal Article
Rouvick Mariano Gama and others
The Journal of Applied Laboratory Medicine, jfag170, https://doi.org/10.1093/jalm/jfag170
Published: 16 November 2026
Image
Published: 13 November 2026
Fig. 1. Lipoprotein(a) in a historical context. Timeline tracing lipoprotein(a) from discovery, through declining interest after negative epidemiologic studies, renewed interest after genetic evidence of causality, guideline adoption, and phase three outcome trials.
Image
Published: 13 November 2026
Fig. 2. Cost-saving through widespread lipoprotein(a) measurement. Flow diagram showing lipoprotein(a)-guided risk reclassification and intensified treatment, with projected reductions in myocardial infarctions, strokes, and premature deaths, alongside net cost savings across high-income countries. Adapt
Image
Published: 13 November 2026
Fig. 3. When to measure lipoprotein(a). Diagram showing how lipoprotein(a) should be measured once in all adults, ideally jointly with the first lipid profile. If previous lipid profiles were taken, then lipoprotein(a) should be included in the next lipid profile. Repeat measurements are relevant if lipo
Image
Published: 13 November 2026
Fig. 4. Potential clinical consequences of delayed lipoprotein(a) testing. Flowchart contrasting simultaneous local lipoprotein(a) with external testing with arrival of lipoprotein(a) results after the standard lipid profile. Optimal clinical care (green) with local lipoprotein(a) measurement, ensuring t
Journal Article
Michaela J Eickhoff
The Journal of Applied Laboratory Medicine, jfag181, https://doi.org/10.1093/jalm/jfag181
Published: 13 November 2026
Journal Article
Muriël Messchaert and others
The Journal of Applied Laboratory Medicine, jfag171, https://doi.org/10.1093/jalm/jfag171
Published: 13 November 2026
Image
Published: 13 November 2026
Fig. 1. Gross and microscopic polybrene crossmatch results. (A), Macroscopic view of major and minor crossmatch tubes. (B), Light micrographs of crossmatch smears at 20× magnification. For image description, please refer to the figure legend and surrounding text.